Ainos, Inc. (AIMD)

Ainos pivots between artificial intelligence and immunology, commercializing machine-readable scent detection and a clinical-stage interferon platform.

Dual Operating Platforms

The AI Nose division develops electronic olfaction technology that translates odors into Smell IDs—machine-readable scent signatures for quality control in semiconductor manufacturing, robotics diagnostics, and senior care facilities. The therapeutics arm advances VELDONA, an oral interferon formulation targeting rare and autoimmune diseases. Neither platform has reached significant scale, but together they position Ainos as a diversified early-stage company rather than a single-product biotech.

Path and Rebranding

Ainos traces its lineage to Amarillo Biosciences (founded 1984), an interferon research outfit. Management renamed and repositioned the company in May 2021 to emphasize dual revenue opportunities and signal a pivot toward AI commercialization. The NASDAQ listing under AIMD reflects this strategic reset and broader investor focus on sensor technologies intersecting with health applications.

At a glance:

• Electronic olfaction and industrial scent sensing
• Low-dose oral interferon for immune-mediated conditions
• Pre-revenue or early-revenue on both platforms
• Houston, Texas headquarters with 1984 founding roots
• Nasdaq-traded; CIK 1014763